Cell Genesys Reports Fourth Quarter and Year-End 20...(interim analysis in the timeframe origin...),Health

has recommended that the study continue. As is customary to preserve

study blinding, the IDMC provided no information to the company other

than the recommendation to continue the trial. The company expects to

have enough events needed to trigger the final analysis of VITAL-1 in

the second half of 2009.

-- Announced in December 2007 the sale of Cell Genesys' lentiviral gene

delivery technology to GBP IP, LLC, an affiliate of GBP Capital, the

majority shareholder in privately held Lentigen Corporation, for $12.0

million.

Presentations at Upcoming Investor Conferences

Members of the Cell Genesys management team plan to present at the following upcoming investor conferences:

-- Cowen & Co.'s 28th Annual Health Care Conference scheduled to occur

March 18 - 20 in Boston, Massachusetts;

-- 11th Annual Lehman Brothers Global Healthcare Conference scheduled to

occur March 18 in Miami, Florida; and

-- BioCentury's Future Leaders in the Biotech Industry Conference

scheduled to occur March 27 in New York City, New York.

Interested parties may access a live audio webcast of the presentation via the investor section of the Cell Genesys website, http://www.cellgenesys.com. A replay of the presentation will be archived on the site for at least 72 hours following the presentation.

Conference Call and Webcast

Members of the Cell Genesys management team will host a conference call today, Thursday, February 28 at 5:00 p.m. ET to discuss today's announcement. Investors may listen to the webcast of the conference call live on the investor section of the Cell Genesys website, http://www.cellgenesys.com. Alternatively, investors may listen to a replay of th
'/>"/>